Ruxolitinib Rutinib Cream 1.5% is a clinically prescribed topical formulation specifically designed for dermatological use in managing inflammatory and pigmentary skin disorders such as eczema (atopic dermatitis) and vitiligo. This cream contains 1.5% concentration of Ruxolitinib, a potent Janus kinase (JAK) inhibitor that targets JAK enzymes involved in inflammatory pathways and immune-mediated skin depigmentation. By inhibiting these enzymes, the cream effectively suppresses inflammation and promotes repigmentation of affected skin areas, improving cosmetic appearance and patient quality of life. Intended for direct application on lesions, Ruxolitinib Rutinib Cream is formulated to ensure optimal skin absorption while maintaining safety profiles under prescribed medical supervision. It is produced under stringent manufacturing protocols aligned with pharmaceutical quality standards to offer a reliable and effective treatment option for patients with chronic dermatologic conditions requiring immune modulation.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Ruxolitinib 1.5% |
| Mechanism of Action | JAK enzyme inhibition to reduce skin inflammation and depigmentation |
| Indications | Atopic dermatitis (eczema), Vitiligo |
| Formulation | Topical cream for direct skin application |
| Prescription Status | Prescription-only medication |
| Manufacturing Standards | Produced under strict pharmaceutical quality controls |
| Usage Guidance | Apply to affected areas as directed by healthcare professional |
| Benefits | Reduces inflammation, aids repigmentation, improves skin appearance |
| Safety Profile | Requires medical supervision to minimize side effects |
| Packaging | Cream tube consistent with dosage instructions |
| Attributes | Description |
|---|---|
| Concentration | 1.5% Ruxolitinib |
| Type of Medication | Topical immunomodulator |
| Therapeutic Class | JAK inhibitor |
| Indicated Skin Conditions | Atopic dermatitis (eczema), Vitiligo |
| Formulation Type | Cream |
| Application Method | Topical application on affected skin |
| Storage Requirements | Store below 30°C, protect from light and moisture |
| Shelf Life | Typically 2 years from manufacture date |
| Regulatory Status | Prescription drug as per Indian medical guidelines |
| Manufacturer Quality Standards | Complies with CGMP (Current Good Manufacturing Practice) |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Ruxolitinib Rutinib Cream 1.5% is primarily prescribed for inflammatory skin conditions such as atopic dermatitis (eczema) and pigmentary disorders like vitiligo.
The cream works by inhibiting Janus kinase (JAK) enzymes involved in the immune and inflammatory pathways, reducing inflammation and promoting repigmentation by restoring skin pigment cells.
Long-term use safety should be determined by a healthcare provider, as continuous inhibition of JAK enzymes requires medical supervision to minimize potential side effects.
Application should be limited to affected areas as prescribed by the healthcare professional; using the cream on large body surfaces should only be done under medical advice.
The cream should be stored below 30°C, away from direct sunlight and moisture to maintain its stability and effectiveness.
Country Of Origin: India
Inclusive of all taxes
You Save: 0
Bengaluru , India
Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler
GST- 29aqtpj8785c1z2
